Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;10(Suppl 13):S1482-S1493.
doi: 10.21037/jtd.2018.05.106.

Immunotherapy in the Asiatic population: any differences from Caucasian population?

Lunxi Peng  1   2 , Yi-Long Wu  1   2
Affiliations
Review

Immunotherapy in the Asiatic population: any differences from Caucasian population?

Lunxi Peng et al. J Thorac Dis. 2018 May.

Abstract

As "Immunotherapy age" is coming, immune checkpoint inhibitors (CPI) therapies have shown favorable clinical benefits and low toxicity profiles in patients with advanced non-small cell lung cancer (NSCLC). While it is a pity that there is a little clear clinical trials evidence about immunotherapy among Asian population. Moreover, since there is an ethnic difference for targeted therapy, what about immunotherapy? Which factors may associate with ethnic differences from Caucasian population to Asiatic population? In this review, we supposed that the characteristics of the much higher proportion of EGFR mutation, hepatitis B virus infection and unexpected immune-related toxicity among Asian patients should be considered.

Keywords: Asiatic population; Immunotherapy; PD-1/PD-L1 inhibitors; ethnic difference; non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The proportion of Asiatic population in previous PD-1/PD-L1 clinical trials. KN, keynote; CM, checkmate.
Figure 2
Figure 2
Combination CPI with other treatments recruiting Asiatic patients in lung cancer. CPI, immune checkpoint inhibitors. durva, durvalumab; treme, tremelimumab; atezo, atezolizumab; C, carboplatin; P, pemetrexed.
Figure 3
Figure 3
When and how to combine EGFR-TKIs with CPI. CPI, immune checkpoint inhibitors.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. 10.3322/caac.21332 - DOI - PubMed
    1. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. 10.1200/JCO.2007.15.0375 - DOI - PubMed
    1. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012;4:120ra17. 10.1126/scitranslmed.3003316 - DOI - PMC - PubMed
    1. Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol 2016;27 Suppl 3:iii42-iii50. 10.1093/annonc/mdw305 - DOI - PMC - PubMed
    1. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92. 10.1056/NEJMoa044238 - DOI - PubMed